Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer

Journal of Reproductive Immunology

Volumn 82, Issue 2, 2009, Pages 106-111

  Foidart, J M ^a,b   Schaaps, J P ^a   Chantraine, F ^a   Munaut, C ^b   Lorquet, S ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Centre Hospitalier Regional de La Citadelle   (Belgium)

Author keywords

Angiotensin 1 receptor auto antibody; Inflammation; Oxidative stress; PE; sEndoglin; sFlt 1

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ENDOGLIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACENTAL GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANTIANGIOGENIC ACTIVITY; CYTOKINE RELEASE; DIFFERENTIATION; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION REGULATION; HELLP SYNDROME; HUMAN; HYPERTENSION; HYPOXIA; IMMUNOREGULATION; INFLAMMATION; INTRAUTERINE GROWTH RETARDATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLACENTA CIRCULATION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TROPHOBLAST;

EID: 84883596957     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2009.09.001     Document Type: Review

References (44)

1. AbdAlla S., Lother H., el Massiery A., and Quitterer U. Increased AT(1) receptor heterodimers in PE mediate enhanced angiotensin II responsiveness. Nat. Med. 7 (2001) 1003-1009
2. Ahmad S., and Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in PE. Circ. Res. 95 (2004) 884-891
3. Ballermann B.J. Glomerular endothelial cell differentiation. Kidney Int. 67 (2005) 1668-1671
4. Baumwell S., and Karumanchi S.A. PE: clinical manifestations and molecular mechanisms. Nephron. Clin. Pract. 106 2 (2007) c72-c81
5. Blouin C.C., Pagé E.L., Soucy G.M., and Richard D.E. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha. Blood 103 (2004) 1124-1130
6. Davidge S.T. Oxidative stress and altered endothelial cell function in PE. Semin. Reprod. Endocrinol. 16 (1998) 65-73
7. De Wolf F., De Wolf-Peeters C., Brosens I., and Robertson W.B. The human placental bed: electron microscopic study of trophoblastic invasion of spiral arteries. Am. J. Obstet. Gynecol. 137 (1980) 58-70
8. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., Gerber H.P., Kikkawa Y., Miner J.H., and Quaggin S.E. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111 (2003) 707-716
9. Foidart J.M., Hustin J., Dubois M., and Schaaps J.P. The human placenta becomes haemochorial at the 13th week of pregnancy. Int. J. Dev. Biol. 36 (1992) 451-453
10. Founds S.A., Conley Y.P., Lyons-Weiler J.F., Jeyabalan A., Allen Hogge W., and Conrad K.P. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta (2008) November 20 (Epub ahead of print)
11. Görlach A., and Bonello S. The cross-talk between NF-kB and HIF-1: further evidence for a significant liaison. Biochem. J. 412 (2008) e17-e19
12. Hubel C.A., McLaughlin M.K., Evans R.W., Hauth B.A., Sims C.J., and Roberts J.M. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in PE, are positively correlated, and decrease within 48 hours post partum. Am. J. Obstet. Gynecol. 174 (1996) 975-982
13. Hung T.H., and Burton G.J. Hypoxia and reoxygenation: a possible mechanism for placental oxidative stress in PE. Taiwan J. Obstet. Gynecol. 45 (2006) 189-200
14. Hustin J., and Schaaps J.P. Echo(cardio)graphic and anatomic studies of the materno trophoblastic border during the first trimester of pregnancy. Am. J. Obstet. Gynecol. 157 1 (1987) 162-168
15. Kolben M., Lopens A., Blaser J., Huber A., Frank M., Wilhelm O., Wilhelm S., Schneider K.T., Ulm K., Tschesche H., et al. Measuring the concentration of various plasma and placenta extract proteolytic and vascular factors in pregnant patients with HELLP syndrome, pre-/eclampsia and highly pathologic Doppler flow values. Gynaekol. Geburtsh. Rundsch. 35 Suppl. 1 (1995) 126-131
16. Kontic-Vucinic O., Terzic M., and Radunovic N. The role of antioxidant vitamins in hypertensive disorders of pregnancy. J. Perinat. Med. 36 4 (2008) 282-290
17. Kuenen B.C., Levi M., Meijers J.C., Kakkar A.K., van Hinsbergh V.W., Kostense P.J., Pinedo H.M., and Hoekman K. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1500-1505
18. Karumanchi S.A., and Lindheimer M.D. Advances in the understanding of eclampsia. Curr. Hypertens. Rep. 10 August (4) (2008) 305-312
19. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P., Sibai B.M., Epstein F.H., Romero R., Thadhani R., and Karumanchi S.A. Soluble endoglin and other circulating antiangiogenic factors in PE. N. Engl. J. Med. 355 (2006) 992-1005
20. Li X., Shams M., Zhu J., Khalig A., Wilkes M., Whittle M., Barnes N., and Ahmed A. Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants. J. Clin. Invest. 101 (1998) 442-454
21. Munaut C., Lorquet S., Pequeux C., Blacher S., Berndt S., Frankenne F., and Foidart J.M. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum. Reprod. 23 June (6) (2008) 1407-1415
22. Maynard S., Epstein F.H., and Karumanchi S.A. PE and angiogenic imbalance. Annu. Rev. Med. 59 (2008) 61-78
23. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., Libermann T.A., Morgan J.P., Sellke F.W., Stillman I.E., Epstein F.H., Sukhatme V.P., and Karumanchi S.A. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in PE. J. Clin. Invest. 111 (2003) 649-658
24. Myatt L., Rosenfield R.B., Eis A.L., Brockman D.E., Greer I., and Lyall F. Nitrotyrosine residues in placenta. Evidence of peroxynitrite formation and action. Hypertension 28 (1996) 488-493
25. Nevo O., Soleymanlou N., Wu Y., Xu J., Kingdom J., Many A., et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (2006) R1085-R1093
26. Pregnancy: Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am. J. Obstet. Gynecol. 183 (2000) S1-S22
27. Qin Z. Newly developed angiotensin II-infused experimental models in vascular biology. Regul. Pept. 150 (2008) 1-6
28. Redman C., and Sargent I.L. Placental stress and PE: a revised view placenta 30, supplement A. Trophoblast Res. 23 (2009) S38-S42
29. Redman C.W., and Sargent I.L. Latest advances in understanding PE. Science 308 (2005) 1592-1594
30. Redman C.W.G., and Sargent I.L. Circulating microparticles in normal pregnancy and PE placenta 29, supplement A. Trophoblast Res. 22 (2008) S73-S77
31. Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A.S., Nizet V., et al. NF-kB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453 (2008) 807-811
32. Robertson W.B., Brosens I., and Dixon H.G. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J. Pathol. Bacteriol. 93 (1967) 581-592
33. Rumbold A., Duley L., Crowther C.A., and Haslam R.R. Antioxidants for preventing PE. Cochrane Database Syst. Rev. January (1) (2008) CD004227
34. Schaaps J.P., and Foidart J.M. Uteroplacental circulation. Rev. Fr. Gynecol. Obstet. 86 (1991) 579-584
35. Schaaps J.P., Tsatsaris V., Goffin F., Brichant J.F., Delbecque K., Tebache M., Collignon L., Retz M.C., and Foidart J.M. Shunting the intervillous space: new concepts in human uteroplacental vascularization. Am. J. Obstet. Gynecol. 192 January (1) (2005) 323-332
36. Shah D.M. Preeclampsia, new insights. Curr. Opin. Nephrol. Hypertens. 16 (2007) 213-220
37. Stella C.L., and Sibai B.M. Preeclampsia: diagnosis and management of the atypical presentation. J. Matern. Fetal Neonatal Med. 19 (2006) 381-386
38. Taylor C.T. Interdependent roles for hypoxia inducible factor and nuclear factor-kB in hypoxic inflammation. J. Physiol. 586 (2008) 4055-4059
39. van Uden P., Kenneth N.S., and Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kB. Biochem. J. 412 (2008) 477-484
40. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., Bdolah Y., Lim K.H., Yuan H.T., Libermann T.A., Stillman I.E., Roberts D., D'Amore P.A., Epstein F.H., Sellke F.W., Romero R., Sukhatme V.P., Letarte M., and Karumanchi S.A. Soluble endoglin contributes to the pathogenesis of PE. Nat. Med. 12 (2006) 642-649
41. Wallukat G., Homuth V., Fischer T., Lindschau C., Horstkamp B., Jupner A., Baur E., Nissen E., Vetter K., Neichel D., Dudenhausen J.W., Haller H., and Luft F.C. Patients with PE develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 103 (1999) 945-952
42. Xia Y., Ramin S.M., and Kellems R.E. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of PE. Hypertension 50 August (2) (2007) 269-275
43. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., and Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349 (2003) 427-434
44. Zhou Y., Damsky C.H., and Fisher S.J. PE is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. J. Clin. Invest. 99 (1997) 2152-2164